Treatment approaches and adherence to urate-lowering therapy for patients with gout
Open Access
- 1 April 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. ume 11, 795-800
- https://doi.org/10.2147/PPA.S97927
Abstract
Treatment approaches and adherence to urate-lowering therapy for patients with gout Thanda Aung,* Gihyun Myung,* John D FitzGerald Division of Rheumatology/Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA *These authors contributed equally to this work Gout is the most common inflammatory arthritis characterized by painful disabling acute attacks. It is caused by hyperuricemia and deposition of urate crystals in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis with joint damage, tophi formation and urate nephropathy. Gout is associated with significant morbidity and health care associated cost. The goal of long-term therapy is to lower the serum urate level to promote dissolution of urate crystals, reduce recurrent acute gout flares, resolve tophi and prevent joint damage. Despite the presence of established gout treatment guidelines and effective medications to manage gout, patient outcomes are often poor. Etiology for these shortcomings is multifactorial including both physician and patient characteristics. Poor adherence to urate-lowering therapy (ULT) is prevalent and is a significant contributor to poor patient outcomes. This article reviews the treatment strategies for the management of hyperuricemia in chronic gout, gaps in quality of care in gout management, factors contributing to poor adherence to ULT and discusses potential interventions to achieve improved gout-related outcomes. These interventions include initiation of prophylactic anti-inflammatory medication when starting ULT, frequent follow-ups, regular serum urate monitoring and improved patient education, which can be achieved through pharmacist- or nurse-assisted programs. Interventions such as these could improve adherence to ULT and, ultimately, result in optimal gout-related outcomes. Keywords: gout, adherence, urate-lowering therapyKeywords
This publication has 47 references indexed in Scilit:
- 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritisArthritis Care & Research, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Gout: why is this curable disease so seldom cured?Annals Of The Rheumatic Diseases, 2012
- Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational studyAnnals Of The Rheumatic Diseases, 2012
- Patients and providers view gout differently: a qualitative studyChronic Illness, 2010
- The Dynamics of Chronic Gout Treatment: Medication Gaps and Return to TherapyThe American Journal of Medicine, 2010
- The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trialArthritis Research & Therapy, 2010
- Comparison of Drug Adherence Rates Among Patients with Seven Different Medical ConditionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendationsAnnals Of The Rheumatic Diseases, 2007
- Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in MenArchives of Internal Medicine, 2005